From Past to Present: The Evolution of Pharmacologic Therapies for Eosinophilic Esophagitis.

Q2 Medicine
Gastroenterology and Hepatology Pub Date : 2025-05-01
Susie Min, Joy W Chang
{"title":"From Past to Present: The Evolution of Pharmacologic Therapies for Eosinophilic Esophagitis.","authors":"Susie Min, Joy W Chang","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Within the evolving landscape of eosinophilic esophagitis (EoE) management are multiple pharmacologic treatment modalities, including proton pump inhibitors (PPIs), swallowed topical corticosteroids, and novel biologic agents. Studies to date on PPIs and corticosteroids have provided valuable insights into how to define the disease, and recently approved biologic therapies are heralding a new era of EoE management. Although progress has been made in treating this complex inflammatory, fibrostenotic disease and in understanding its pathophysiology, several knowledge gaps persist and continue to be investigated. In addition, unknowns exist regarding the long-term safety and efficacy of new EoE treatments and how to position therapies in diverse patient populations. This article aims to provide historical context for the current landscape of pharmacologic treatments in EoE and perspectives on how future development may improve understanding and management of this complex disease.</p>","PeriodicalId":52498,"journal":{"name":"Gastroenterology and Hepatology","volume":"21 5","pages":"298-303"},"PeriodicalIF":0.0000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12100528/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gastroenterology and Hepatology","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Within the evolving landscape of eosinophilic esophagitis (EoE) management are multiple pharmacologic treatment modalities, including proton pump inhibitors (PPIs), swallowed topical corticosteroids, and novel biologic agents. Studies to date on PPIs and corticosteroids have provided valuable insights into how to define the disease, and recently approved biologic therapies are heralding a new era of EoE management. Although progress has been made in treating this complex inflammatory, fibrostenotic disease and in understanding its pathophysiology, several knowledge gaps persist and continue to be investigated. In addition, unknowns exist regarding the long-term safety and efficacy of new EoE treatments and how to position therapies in diverse patient populations. This article aims to provide historical context for the current landscape of pharmacologic treatments in EoE and perspectives on how future development may improve understanding and management of this complex disease.

从过去到现在:嗜酸性粒细胞性食管炎药物治疗的演变。
在嗜酸性粒细胞性食管炎(EoE)的治疗中,有多种药物治疗方式,包括质子泵抑制剂(PPIs)、口服皮质类固醇和新型生物制剂。迄今为止,关于质子泵抑制剂和皮质类固醇的研究为如何定义这种疾病提供了有价值的见解,最近批准的生物疗法预示着EoE管理的新时代。尽管在治疗这种复杂的炎症性纤维狭窄疾病和了解其病理生理方面取得了进展,但仍存在一些知识空白,并继续进行研究。此外,关于新的EoE治疗的长期安全性和有效性以及如何在不同的患者群体中定位治疗存在未知因素。本文旨在为EoE的药物治疗现状提供历史背景,并展望未来的发展如何提高对这种复杂疾病的理解和管理。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Gastroenterology and Hepatology
Gastroenterology and Hepatology Medicine-Gastroenterology
CiteScore
3.20
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信